Quest Diagnostics and Genomic Vision Collaborate on New Genome-Based Clinical Testing Services

Quest Diagnostics Inc. (Madison, NJ, USA), global provider of diagnostic testing, services, and information and Genomic Vision (Paris, France), a biotechnology company specializing in the development of molecular diagnostics, announced their exclusive collaboration agreement based on Genomic Vision's proprietary molecular combing genomic-analysis technology. This technology detects genetic mutations by manipulating coils of DNA into straight chains, enabling direct high-resolution analysis of targeted areas of the human genome.

The multiyear collaboration agreement gives Quest Diagnostics exclusive rights to develop and offer laboratory-testing services based on Genome Vision's molecular combing technique, also known as DNA combing, in the USA, India, and Mexico. Genomic Vision will market new testing services that result from the collaboration in Europe, excluding the UK, the Middle East, and Africa.

"Genomic Vision's DNA combing technology is a potential game changer in genomic analysis," said Jay G. Wohlgemuth, MD, vice president, science and innovation, Quest Diagnostics. "Similar to how microarrays introduced an entirely new concept to analyze genetic alterations, DNA combing, by facilitating analysis of single DNA molecules, could radically improve our understanding of disease-causing mutations and, in turn, clinical testing and drug development."

"Quest Diagnostics has a superb track record of turning cutting-edge genetic research and techniques into clinically validated diagnostics," said Founder, CEO and molecular combing inventor, Dr. Aaron Bensimon. "Our collaboration with Quest Diagnostics puts molecular combing on track to fulfill its potential to help improve disease detection and new drug development for patients worldwide."

Related Links:
Quest Diagnostics
Genomic Vision